One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, allowing it to evade the antibody response generated by vaccines.
Massachusetts Institute of TechnologySep 20 2024
By bringing together the physical and life sciences, we shed light on some basic immunological questions that helped develop this two-dose schedule to mimic the multiple-dose regimen." In the new study, the MIT team investigated how this response develops and explored whether they could achieve the same effect using a smaller number of vaccine doses.
Using a computational model, the researchers explored what was happening in each of these dosing scenarios. This work showed that when all of the vaccine is given as one dose, most of the antigen gets chopped into fragments before it reaches the lymph nodes. Lymph nodes are where B cells become activated to target a particular antigen, within structures known as germinal centers.
Antibodies Antibody Antigen Cancer Cell Computational Modeling Immune Response Immune System Immunology Lymph Node Lymph Nodes Nanoparticle Protein Research T-Cell Vaccine Virus
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Northampton Market returns home after £10m faceliftThe historic market has new stalls from Italy, new paving, new lighting and new trees.
Read more »
New Black Ops 6 beta playlist update adds new mode and two new mapsThe latest Call of Duty Black Ops 6 playlist update has added a brand new mode to keep playing entertained during the beta.
Read more »
New study highlights potential of childhood immunization against HIVResearch at Weill Cornell Medicine suggests that childhood immunization against HIV could one day provide protection before risk of contracting this potentially fatal infection dramatically increases in adolescence.
Read more »
New study reveals relationship between HIV risk factors for LGBTQ+ youthA new study has uncovered empirical evidence that shows what researchers have long suspected about HIV risk—that having multiple risk factors is much worse than having only one.
Read more »
Promising new approach to combat HIVResearchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing antiretroviral therapy.
Read more »
New study increases understanding of HIV drug's negative effects on the brainEfavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50% of patients.
Read more »